

## **Corium to Present at Upcoming Healthcare Investor Conferences**

February 6, 2018

MENLO PARK, Calif., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that the company will be participating in and hosting 1x1 investor meetings at the following February 2018 conferences:

- BIO CEO & Investor Conference Peter Staple, Corium's Chairman and Chief Executive Officer, will present in New York City on Tuesday, February 13, 2018 at 10:45 AM Eastern time. A live webcast of Corium's presentation may be accessed <a href="here">here</a>.
- <u>LEERINK Partners 7th Annual Global Healthcare Conference</u> Mr. Staple will present in New York City on Wednesday, February 14, 2018 at 2:30 PM Eastern time. A live webcast of Corium's presentation may be accessed <u>here</u>.

The webcasts and presentations can also be accessed by visiting "Events & Presentations" in the Investors section of the Company's website at <a href="https://www.coriumintl.com">www.coriumintl.com</a>. They will be archived on the Corium website for two weeks following the presentations.

## **About Corium**

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems. Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer's disease. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Mayne Pharma and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. In addition to its proprietary Alzheimer's program, the company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics and additional transdermal products that are being developed with other partners. For further information, please visit www.coriumintl.com.

Corplex™ and MicroCo® are registered trademarks of Corium International, Inc.

Source: Corium

Investor and Media Contact: SMP Communications Susan M. Pietropaolo susan@smpcommunications.com (201) 923-2049



Source: Corium International, Inc.